Advocacy intelligence hub — real-time data for patient organizations
Remicade: FDA approved
For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy
Colazal: FDA approved
Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal beyond 8 weeks in children (ages 5-17) and 12 weeks in adults have not been established.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Colazal
Salix Pharmaceuticals, Inc.
Remicade
(infliximab)Orphan drugJanssen Biotech, Inc.
Tumor Necrosis Factor Blocker [EPC]
12.1 Mechanism of Action Infliximab neutralizes the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms o...
Colazal
(Balsalazide disodium)Orphan drugSalix Pharmaceuticals, Inc.
12.1 Mechanism of Action Balsalazide disodium is delivered intact to the colon where it is cleaved by bacterial azoreduction to release equimolar quan...
PHYTONADIONE PHYTONADIONE
(PHYTONADIONE)Orphan drugstandardDr.Reddy's Laboratories Inc
View all NON RARE IN EUROPE: Ulcerative colitis specialists →